Logo image of TLRY

TILRAY BRANDS INC (TLRY) Stock Fundamental Analysis

NASDAQ:TLRY - Nasdaq - US88688T1007 - Common Stock - Currency: USD

1.07  +0.07 (+7%)

After market: 1.06 -0.01 (-0.93%)

Fundamental Rating

2

Taking everything into account, TLRY scores 2 out of 10 in our fundamental rating. TLRY was compared to 195 industry peers in the Pharmaceuticals industry. TLRY has a bad profitability rating. Also its financial health evaluation is rather negative. TLRY is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TLRY had negative earnings in the past year.
TLRY had a negative operating cash flow in the past year.
TLRY had negative earnings in each of the past 5 years.
TLRY had negative operating cash flow in 4 of the past 5 years.
TLRY Yearly Net Income VS EBIT VS OCF VS FCFTLRY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B

1.2 Ratios

The Return On Assets of TLRY (-5.94%) is better than 76.34% of its industry peers.
The Return On Equity of TLRY (-7.17%) is better than 79.57% of its industry peers.
Industry RankSector Rank
ROA -5.94%
ROE -7.17%
ROIC N/A
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
TLRY Yearly ROA, ROE, ROICTLRY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

TLRY has a Gross Margin of 30.47%. This is comparable to the rest of the industry: TLRY outperforms 53.76% of its industry peers.
TLRY's Gross Margin has declined in the last couple of years.
TLRY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
TLRY Yearly Profit, Operating, Gross MarginsTLRY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

More info and screens

3

2. Health

2.1 Basic Checks

TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
TLRY has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TLRY has been increased compared to 5 years ago.
The debt/assets ratio for TLRY has been reduced compared to a year ago.
TLRY Yearly Shares OutstandingTLRY Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
TLRY Yearly Total Debt VS Total AssetsTLRY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

Based on the Altman-Z score of 0.06, we must say that TLRY is in the distress zone and has some risk of bankruptcy.
TLRY has a Altman-Z score of 0.06. This is comparable to the rest of the industry: TLRY outperforms 53.76% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that TLRY is not too dependend on debt financing.
TLRY has a Debt to Equity ratio of 0.10. This is comparable to the rest of the industry: TLRY outperforms 47.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z 0.06
ROIC/WACCN/A
WACC9.03%
TLRY Yearly LT Debt VS Equity VS FCFTLRY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

2.3 Liquidity

TLRY has a Current Ratio of 2.54. This indicates that TLRY is financially healthy and has no problem in meeting its short term obligations.
TLRY has a Current ratio (2.54) which is in line with its industry peers.
A Quick Ratio of 1.58 indicates that TLRY should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.58, TLRY is not doing good in the industry: 62.90% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.54
Quick Ratio 1.58
TLRY Yearly Current Assets VS Current LiabilitesTLRY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 86.05% over the past year.
The Revenue has grown by 18.38% in the past year. This is quite good.
The Revenue has been growing by 78.86% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)86.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.12%
Revenue 1Y (TTM)18.38%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%8.87%

3.2 Future

TLRY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.07% yearly.
The Revenue is expected to grow by 7.58% on average over the next years.
EPS Next Y40.17%
EPS Next 2Y31.17%
EPS Next 3Y24.74%
EPS Next 5Y18.07%
Revenue Next Year14.2%
Revenue Next 2Y9.83%
Revenue Next 3Y8.35%
Revenue Next 5Y7.58%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TLRY Yearly Revenue VS EstimatesTLRY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TLRY Yearly EPS VS EstimatesTLRY Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TLRY. In the last year negative earnings were reported.
Also next year TLRY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLRY Price Earnings VS Forward Price EarningsTLRY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, TLRY is valued a bit cheaper than the industry average as 79.03% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 33.4
TLRY Per share dataTLRY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as TLRY's earnings are expected to grow with 24.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.17%
EPS Next 3Y24.74%

More info and screens

0

5. Dividend

5.1 Amount

TLRY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TILRAY BRANDS INC

NASDAQ:TLRY (2/5/2025, 8:00:01 PM)

After market: 1.06 -0.01 (-0.93%)

1.07

+0.07 (+7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-10 2025-01-10/bmo
Earnings (Next)N/A N/A
Inst Owners11.18%
Inst Owner Change-0.28%
Ins Owners0.31%
Ins Owner Change0.02%
Market Cap966.52M
Analysts72
Price Target1.94 (81.31%)
Short Float %14.92%
Short Ratio3.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-77.02%
Min EPS beat(2)-145.1%
Max EPS beat(2)-8.93%
EPS beat(4)0
Avg EPS beat(4)-91.89%
Min EPS beat(4)-145.1%
Max EPS beat(4)-8.93%
EPS beat(8)1
Avg EPS beat(8)-435.3%
EPS beat(12)2
Avg EPS beat(12)-369.86%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.61%
Min Revenue beat(2)-10.57%
Max Revenue beat(2)-4.66%
Revenue beat(4)0
Avg Revenue beat(4)-5.74%
Min Revenue beat(4)-10.57%
Max Revenue beat(4)-0.75%
Revenue beat(8)1
Avg Revenue beat(8)-1.66%
Revenue beat(12)1
Avg Revenue beat(12)-2.67%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.72%
PT rev (3m)-14.19%
EPS NQ rev (1m)8.32%
EPS NQ rev (3m)18.51%
EPS NY rev (1m)-75.95%
EPS NY rev (3m)-77.33%
Revenue NQ rev (1m)-3.24%
Revenue NQ rev (3m)7.43%
Revenue NY rev (1m)-1.16%
Revenue NY rev (3m)-2.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.17
P/FCF N/A
P/OCF N/A
P/B 0.28
P/tB 1.6
EV/EBITDA 33.4
EPS(TTM)-0.3
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0.92
BVpS3.84
TBVpS0.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.94%
ROE -7.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.47%
FCFM N/A
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
F-Score6
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA 12.11
Cap/Depr 24.08%
Cap/Sales 3.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.54
Quick Ratio 1.58
Altman-Z 0.06
F-Score6
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)20.35%
Cap/Depr(5y)159.29%
Cap/Sales(3y)4.15%
Cap/Sales(5y)16.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.12%
EPS Next Y40.17%
EPS Next 2Y31.17%
EPS Next 3Y24.74%
EPS Next 5Y18.07%
Revenue 1Y (TTM)18.38%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%8.87%
Revenue Next Year14.2%
Revenue Next 2Y9.83%
Revenue Next 3Y8.35%
Revenue Next 5Y7.58%
EBIT growth 1Y38.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year136.59%
EBIT Next 3Y37.95%
EBIT Next 5Y24.25%
FCF growth 1Y9.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.73%
OCF growth 3YN/A
OCF growth 5YN/A